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Abstract
Objective: To estimate the value of first or second trimester placental growth factor (PlGF) as an additional antenatal
screening marker for Down syndrome.
Design: Nested case-control study.
Setting: Antenatal screening service.
Population or Sample: 532 Down syndrome pregnancies and 1,155 matched unaffected pregnancies.
Methods: Stored maternal serum samples (240uC) were assayed for PlGF. Monte Carlo simulation was used to estimate the
screening performance of PlGF with the Combined, Quadruple, serum Integrated and Integrated tests.
Main Outcome Measures: Median PlGF levels in affected and unaffected pregnancies and screening performance
(detection rates [DR] for specified false-positive rates [FPR] and vice versa).
Results: First trimester median PlGF was 15%, 28% and 39% lower in Down syndrome than unaffected pregnancies at 11, 12
and 13 completed weeks’ gestation respectively (all p,0.001). Second trimester median PlGF was 31% lower at 14 weeks
(p,0.001), and the difference decreased (6% lower at 17 weeks). At a 90% DR with first trimester markers measured at 13
weeks, adding PlGF decreased the FPR from 11.1 to 5.1% using the Combined test, 9.3% to 4.5% using the serum Integrated
test, and 3.4% to 1.5% using the Integrated test (or 1.5 to 1.4% with first trimester markers measured at 11 weeks). Adding
PlGF to the Quadruple test (measured at 15 weeks) decreased the FPR from 10.0% to 9.6% at a 90% DR.
Conclusions: First trimester PlGF measurements improve the performance of antenatal screening for Down syndrome using
the Combined, serum Integrated and Integrated tests. Second trimester PlGF measurements are of limited value.
Citation: Wald NJ, Bestwick JP, George LM, Huttly WJ (2012) Antenatal Screening for Down Syndrome Using Serum Placental Growth Factor with the Combined,
Quadruple, Serum Integrated and Integrated Tests. PLoS ONE 7(10): e46955. doi:10.1371/journal.pone.0046955
Editor: Olga Y. Gorlova, The University of Texas M. D. Anderson Cancer Center, United States of America
Received July 16, 2012; Accepted September 7, 2012; Published October 3, 2012
Copyright:  2012 Wald et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: PerkinElmer provided the PlGF assay kits free of charge. No additional external funding was received for this study. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have the following interests: PerkinElmer provided the PlGF assay kits free of charge. N. Wald has a patent for the Integrated
test as follows: Application No.; Country; Filing Date; Patent No.; Issue/Grant Date 09/301,621; US; 29.04.99; 6,573,103; 03.06.03 36213/99; Australia; 29.04.99;
763171; 31.10.06 2330538; Canada; 29.04.99; 2330538; 11.09.07 99918188; Europe; 29.04.99; 1076824; 14.06.06 139302; Israel; 29.04.99; 139302; 26.10.05 With
others, he held a patent in connection with the use of uE3 as a second trimester screening marker in prenatal screening for Down syndrome, although this has
now expired. He is Director of Logical Medical Systems Ltd, which produces software for the interpretation of Down syndrome screening tests. There are no
further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data
and materials, as detailed online in the guide for authors.
* E-mail: n.j.wald@qmul.ac.uk
Introduction
Placental growth factor (PlGF) is an angiogenic hormone which
has been shown to be useful in late first trimester and early second
trimester antenatal screening for pre-eclampsia. First trimester
levels were found to be 36% lower in women who developed early
pre-eclampsia compared to unaffected controls [1] and early
second trimester levels were 30% lower. [2] The value of PlGF in
screening for Down syndrome is less clear. Five studies have
reported results on PlGF measured in the late first trimester (11 to
13 weeks’ gestation). Four of these showed, on average, reduced
PlGF levels in Down syndrome compared with unaffected
pregnancies (22% [3], 24% [4], 29% [5] and 38% [6] lower
based on 91, 70, 90 and 42 affected pregnancies respectively) and
one study found a higher level in affected pregnancies (26% higher
based on 45 affected pregnancies [7]). In the second trimester three
studies reported PlGF results; one showed reduced levels (33%
lower based on 24 affected prengnancies [8]), one increased levels
(42% higher based on 36 affected pregnancies [9]) and one no
material difference in Down syndrome compared with unaffected
pregnancies (1% higher based on 39 affected pregnancies [10]).
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The uncertain value of PlGF in antenatal screening for Down
syndrome prompted us to investigate the matter further by
comparing the screening performance with and without (i) first
trimester PlGF measurements added to the Combined test (nuchal
translucency [NT], free b-human chorionic gonadotrophin [hCG]
and pregnancy associated plasma protein A [PAPP-A] measured
between 11 and 13 weeks’ gestation), (ii) second trimester PlGF
measurements added to the early second trimester Quadruple test
(alphafetoprotein [AFP], unconjugated oestriol [uE3], free b-hCG
and inhibin-A measured between 14 and 22 weeks’ gestation), (iii)
first trimester PlGF measurements added to the Integrated test
(first trimester NT and PAPP-A and second trimester AFP, uE3
free b-hCG and Inhibin-A) and serum Integrated test (Integrated
test without NT) and (iv) early second trimester PlGF measure-
ments added to the Integrated and serum Integrated tests.
Methods
According to guidelines from the National Research Ethics
Committee, our research does not require research ethics
committee approval as serum samples were collected as part of a
routine antenatal screening programme. Women are informed of
the possible subsequent use of samples in research or screening
programme audits, so they could indicate to the programme staff
that they did not want their samples used. The research analysis
was conducted on anonymised samples and data.
We identified 532 Down syndrome singleton pregnancies
screened at the Wolfson Insititute of Preventive Medicine between
February 2000 and May 2010 from the screening service records
and by linkage to data from the National Cytogenetic Register
held at the Wolfson Institute. Among the 532 affected pregnancies,
289 were screened using the Combined test (from February 2005),
217 using the Quadruple test and 26 using the Integrated test
(from March 2003). Each affected pregnancy was matched with 2
(Combined and Quadruple test) or 5 (Integrated test) unaffected
control pregnancies for gestational age (same day), maternal age
(in 5 year categories) and length of storage (in six-month
categories).
Frozen (240uC) stored samples were thawed and assayed for
placental growth factor using the AutoDELPHIAH PlGF kit
(Perkin Elmer). The samples were assayed ‘‘blind’’ i.e. without
knowledge of whether the samples were from a Down syndrome or
unaffected pregnancy. The inter-assay coefficient of variation was
7.5% and intra-assay coefficient of variation 3.9%. Serum from
women screened using the Combined and Integrated tests was
used to assess first trimester PlGF, and serum from women
screened using the Quadruple and Integrated tests was used to
assess second trimester PlGF.
PlGF concentrations were expressed as multiples of the median
(MoM) for unaffected pregnancies of the same gestational age by
performing a regression of the log median PlGF against the
median gestational age in 2-day categories for first trimester
measurements and weekly categories for second trimester mea-
surements (weighted by the number of women in each category)
and dividing PlGF concentrations by the regressed (i.e. expected)
concentration for the same gestational age. MoM values were
adjusted for maternal weight by performing a regression of the log
median MoM values against weight in unaffected pregnancies and
dividing MoM values by the regressed value for the same weight.
Associations between weight adjusted PlGF MoM values and
maternal smoking and ethnicity were also determined and MoM
values further adjusted as required. The change in median MoM
in Down syndrome pregnancies was investigated by performing a
regression of the median PlGF MoM against the median
gestational age in 2-day categories for first trimester measurements
and weekly categories for second trimester measurements
(weighted by the number of women in each category; 19 to 22
weeks were combined into one category due to the small numbers
of Down syndrome pregnancies with PlGF measurements beyond
18 weeks’ gestation). Probability plots and, if appropriate, the
approximate point of risk reversal (to ensure risk estimation is a
monotonic function of the marker value [11]) were used to specify
truncation limits within which the range of values for PlGF
approximately followed log-Gaussian distributions in affected and
unaffected pregnancies.
Median PlGF MoM values were used as the measure of central
tendency to avoid the influence of outliers and their log values as
estimates of the means. Standard deviations (log) were calculated
by regression of the points on the probability plot between the 10th
and 90th centiles and correlation coefficients with the standard
Down syndrome screening markers (first trimester NT, free b-
hCG and PAPP-A and second trimester AFP, uE3 free b-hCG
and Inhibin-A) were calculated after excluding points more than
3.5 standard deviations from the mean (correlations between first
trimester PlGF and second trimester markers, and second
trimester PlGF and first trimester markers were estimated using
data from women screened using the Integrated test). Log means
and standard deviations of the standard Down syndrome screening
markers and correlation coefficients were taken from the SURUSS
report.[12–15].
Monte Carlo simulation was used to estimate screening
performance instead of numerical integration as used previous-
ly[12–15] (because Monte Carlo simulation is computationally
faster). Hypothetical random samples of 250,000 Down syndrome
and 250,000 unaffected pregnancies were generated based on the
specified Gaussian distributions. Each simulated pregnancy was
assigned a maternal age based on the maternal age distribution of
Table 1. Number of pregnancies classified according to
screening test, gestational age when screened, and selected
characteristics of the Down syndrome and unaffected
pregnancies.
Down syndrome
(N=532)
Unaffected
(N=1,152)
Screening test received
Combined test 289 576
Quadruple test 217 433
Integrated test 26 143
Median gestational age (days)
First trimester 88 88
Second trimester 114 114
Median maternal age at EDD 37 37
Median maternal weight (kg) 66 66
Smoking (%) 5.8 7.7
Ethnicity (%)
Afro-Caribbean 9.2 10
White 72 73
South Asian 6.5 5.7
Oriental 2.6 3.3
Other 10.2 8.3
EDD: expected date of delivery.
doi:10.1371/journal.pone.0046955.t001
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Figure 1. First trimester (a) and second trimester (b) placental growth factor (PlGF) according to gestational age in Down syndrome
pregnancies (circles) and medians in 2-day intervals* (a) and weekly intervals (b) in unaffected pregnancies (squares, with 95%
confidence intervals) together with expected (regressed) median in unaffected pregnancies.
doi:10.1371/journal.pone.0046955.g001
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Figure 2. First trimester (a) and second trimester (b) placental growth factor (PlGF) maternal weight, smoking and ethnicity
adjusted MoM values according to gestational age and medians (squares, with 95% confidence intervals) in 2-day intervals* (a)
and weekly intervals (b) in Down syndrome pregnancies together with expected (regressed) median.
doi:10.1371/journal.pone.0046955.g002
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maternities in England and Wales 2006–2008 [16] (instead of
1996–1998 as used previously, so screening performance figures of
tests without PlGF will be expected to be a little different from
those previously reported.[12–15]) and the maternal age-specific
odds of an affected livebirth. [17,18] For each simulated
pregnancy, the predicted risk of having a pregnancy with Down
syndrome in the early second trimester was calculated by
multiplying the maternal age specific odds of having an affected
live birth adjusted to early mid-trimester by multiplying by 1/0.77
to allow for the general fetal loss in Down syndrome pregnancies
from this time in pregnancy until term [19] by the likelihood ratio
(for a given set of marker values) obtained from the overlapping
multivariate Gaussian distributions of marker levels in affected and
unaffected pregnancies. A woman was classified as screen positive
if her risk of having a pregnancy affected with Down syndrome
was greater than or equal to a specified risk cut-off level. Screening
performance estimates were calculated as the detection rate (DR)
for false-positive rates (FPR) of 1, 3 and 5%, the FPR for DR’s of
85, 90 and 95% and the DR and FPR for early second trimester
risk cut-offs of 1 in 100, 1 in 150 and 1 in 200.
Results
Table 1 shows the number of pregnancies screened classified
according to test, gestational age when screened, and selected
characteristics of the Down syndrome and unaffected pregnancies.
The distributions of the variables in the two groups were similar.
Figure 1a shows the concentration of late first trimester (11–13
completed weeks) PlGF in affected pregnancies according to
gestational age together with the expected (regressed) median
concentration in unaffected pregnancies. The median PlGF in
unaffected pregnancies increased by 31% per week of gestation
(p,0.001). Figure 1b shows the corresponding data for early
second trimester PlGF (14–22 completed weeks). The median
PlGF in unaffected pregnancies increased by 19% per week of
gestation (p,0.001). In unaffected pregnancies, first trimester
PlGF MoM values decreased by 1.3% per 5 kg increase in
maternal weight (p = 0.031) and second trimester PlGF MoM
values decreased by 3.1% per 5 kg increase (p = 0.002);
Smokers had higher weight adjusted PlGF MoM values than
non-smokers; 32% higher in the first trimester (95% confidence
interval 25% to 61%) and 36% higher in the second trimester
(95% confidence interval 11% to 59%). First trimester PlGF MoM
values were 18% higher in Afro-Caribbean women compared with
white women (95% confidence interval 7% to 35%) and second
trimester MoM values 30% higher (95% confidence interval 9% to
54%). First trimester weight adjusted PlGF MoM values were
therefore divided by 1.32 in smokers and by 1.18 in Afro-
Caribbean women; second trimester MoM values by 1.36 in
smokers and 1.30 in Afro-Caribbean women. There were no
significant increases or decreases in either first or second trimester
weight adjusted PlGF MoM values in other ethnic groups.
Figure 2a shows the first trimester PlGF MoM values (after
adjustment for maternal weight, smoking and Afro-Caribbean
ethnicity) in Down syndrome pregnancies according to gestational
age together with the expected (regressed) median MoM and the
corresponding results for second trimester PlGF. The median
MoM values decreased by 15% per week (p = 0.003), with the
median MoM at 11, 12 and 13 completed weeks’ gestation being
0.85 (95% confidence interval, CI 0.76 to 0.95), 0.72 (95% CI 0.68
to 0.76) and 0.61 (95% CI 0.55 to 0.67) respectively. Table 2
shows the observed and regressed median MoM values at each
completed week of gestation.
Figure 2b and table 2 show that the median second trimester
MoM increased by 11% per week (p,0.001), with the median
MoM at 14, 15, 16 completed weeks’ gestation being 0.69 (95% CI
0.54 to 0.89), 0.77 (95% CI 0.65 to 0.91) and 0.85 (95% CI 0.75 to
0.97) respectively. The median MoM at 17, completed weeks’
gestation was 0.94 (95% CI 0.80 to 1.12) and at 18–22 weeks was
1.15 (95% CI 0.82 to 1.62); neither statistically significantly
different from the median in unaffected pregnancies (1.0 MoM).
Therefore, screening performance estimates for PlGF were not
considered for measurements of PlGF beyond 16 weeks’ gestation.
Inspection of probability plots of PlGF MoM values in Down
syndrome and unaffected pregnancies showed that the distribu-
tions were reasonably Gaussian between 0.4 to 2.5 MoM (see
figure in Appendix S1). The standard deviations of the first and
second trimester log PlGF MoM values were, respectively, 0.1705
and 0.2243 in affected pregnancies and 0.1556 and 0.1786 in
unaffected pregnancies. As a single marker the PlGF detection
rates for a 5% false-positive rate were 14%, 26% and 41% at 11,
12 and 13 completed weeks respectively and 27%, 21% and 16%
at 14, 15 and 16 weeks.
Table 2. Observed and regressed median PlGF MoM in Down syndrome pregnancies according to gestational age.
Completed week of gestation Number of affected pregnancies Observed Regressed
Median MoM Median MoM (95% CI)* p-value
First trimester
11 48 0.82 0.85 (0.76 to 0.95) 0.011
12 164 0.71 0.72 (0.68 to 0.76) ,0.001
13 89 0.68 0.61 (0.55 to 0.67) ,0.001
Second trimester
14 13 0.66 0.69 (0.54 to 0.89) 0.019
15 63 0.77 0.77 (0.65 to 0.91) 0.016
16 97 0.82 0.85 (0.75 to 0.97) 0.031
17 27 1.12 0.94 (0.80 to 1.12) 0.368
18–22 24 1.06 1.15 (0.82 to 1.62)** 0.279
*Median MoM at completed week (week+3 days).
**Regressed median MoM at 135.5 days gestation (median gestational at 18–22 completed weeks).
doi:10.1371/journal.pone.0046955.t002
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Table 3 shows the screening performance of the Combined,
Quadruple, serum Integrated and Integrated tests with and
without the addition of PlGF at specified detection rates and at
specified false-positive rates. The addition of a first trimester
measurement of PlGF improves the screening performance of
the Combined test; at a 90% detection rate the false-positive rate
decreased from 6.7% to 6.1% with markers measured at 11
completed weeks of gestation and from 11.1% to 5.1% at 13
completed weeks’ gestation. The addition of a second trimester PlGF
measurement to the Quadruple test had little influence on
screening performance; for example, at a 90% detection rate the
false-positive rate decreased from 10.0% to 9.6% if PlGF is
measured at 15 completed weeks’ gestation. Results with PlGF
measured at 14 and 16 completed weeks’ gestation are similar
[9.4% and 9.7% respectively] and so second trimester screening
performance estimates are not shown in the Table.
Table 3 shows that at a 90% detection rate the addition of first
trimester PlGF measurement to the Integrated test reduces the false-
positive rate from 1.5% to 1.4% at 11 completed weeks’ gestation
and from 3.4% to 1.5% at 13 completed weeks. The addition of a
second trimester PlGF measurement at 15 completed weeks’ gestation
to the Integrated test reduces the false positive rate from 1.5% to
1.3% when first trimester markers are measured at 11 completed
weeks’ gestation and from 3.4% to 2.9% when first trimester
markers are measured at 13 completed weeks. The results are
similar if PlGF is measured at 14 or 16 completed weeks’ gestation.
Table 3. Screening performance according to detection and false-positive rates of the Combined, Quadruple and Integrated tests
with and without the addition of first or second trimester placental growth factor (PlGF) according to gestational age markers are
measured.
Gestational age
first trimester
markers measured
(completed weeks) DR (%) for FPR of:- FPR (%) for DR of:-
Test 1% 3% 5% 85% 90% 95%
Comined
Without PlGF 11 76 84 88 3.2 6.7 16.6
12 74 83 86 4.2 8.6 19.8
13 70 79 84 5.9 11.1 23.0
With PlGF 11 77 85 89 2.9 6.1 15.3
12 77 85 89 2.8 6.1 14.9
13 78 86 90 2.4 5.1 12.4
Quadruple
Without PlGF – 64 77 83 5.9 10.0 19.6
With PlGF at 15 – 66 78 84 5.7 9.6 18.9
completed weeks
Serum Integrated
Without PlGF 11 72 83 87 3.8 7.2 15.4
12 69 81 86 4.7 8.4 17.3
13 67 79 84 5.3 9.3 18.6
With first 11 73 84 88 3.4 6.5 13.9
trimester PlGF 12 73 84 88 3.4 6.1 12.9
13 76 87 91 2.5 4.5 9.7
With second 11 74 84 88 3.3 6.4 14.1
trimester PlGF at 15 12 71 82 87 4.1 7.6 16.0
completed weeks 13 69 81 86 4.7 8.5 17.2
Integrated
Without PlGF 11 88 93 95 0.6 1.5 5.0
12 86 92 94 0.8 2.2 6.6
13 82 89 92 1.5 3.4 9.1
With first 11 88 93 95 0.5 1.4 4.5
trimester PlGF 12 88 93 95 0.6 1.5 4.6
13 88 94 96 0.6 1.5 4.2
With second 11 89 94 95 0.5 1.3 4.4
trimester PlGF at 15 12 87 92 94 0.7 1.8 5.8
completed weeks 13 84 90 93 1.3 2.9 8.1
doi:10.1371/journal.pone.0046955.t003
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As with the Integrated test, the addition of a first trimester PlGF
measurement to the serum Integrated test improves screening
performance but a second trimester PlGF has little effect (Table 3).
Table 4 shows, in a similar way to Table 3, results according to risk
cut-off. Table 5 shows the overall screening performance (first
trimester markers measured at 11–13 weeks’ gestation) with and
without the addition of first and second trimester PlGF to the
Combined, Serum Integrated and Integrated tests assuming equal
numbers of women screened at each week of gestation in the first
trimester. The addition of a first trimester PlGF measurement
decreases the overall false-positive rate by about one third. For
example, at a 90% detection rate, the overall Combined test false-
positive rate decreases from 8.8% to 5.8% and the overall
Integrated test false-positive rate from 8.3% to 5.7%.
Probability plots of PlGF MoM values and the statistical
parameters (means standard deviations, correlation coefficients
and truncation limits) used in this study for the estimation of
screening performance are shown in the Appendix S1.
Discussion
In the late first trimester our results show that PlGF levels are
reduced in Down syndrome pregnancies at 11, 12 and 13
completed weeks of gestation. The levels are lower at 12 than 11
weeks and lower at 13 than at 12 weeks. Correspondingly, the
improvement in screening performance due to the addition of
Table 4. Screening performance according to risk cut-off of the Combined, Quadruple and Integrated tests with and without the
addition of first or second trimester placental growth factor (PlGF) according to gestational age markers are measured.
Gestational age
first trimester
markers measured
(completed weeks) Risk cut-off (early second trimester)
1 in 100 1 in 150 1 in 200
Test DR (%) FPR (%) OAPR DR (%) FPR (%) OAPR DR (%) FPR (%) OAPR
Comined
Without PlGF 11 82 2.0 1:9 84 3.0 1:12 86 3.9 1:16
12 80 2.1 1:9 83 3.0 1:13 85 3.9 1:16
13 77 2.3 1:11 81 3.5 1:15 83 4.6 1:19
With PlGF 11 82 1.9 1:8 85 2.8 1:12 87 3.7 1:15
12 82 1.9 1:8 85 2.7 1:11 87 3.6 1:15
13 83 1.9 1:8 86 2.8 1:11 88 3.5 1:14
Quadruple
Without PlGF – 78 3.2 1:14 82 4.6 1:19 85 5.8 1:24
With PlGF at 15 – 78 3.0 1:13 82 4.2 1:18 85 5.5 1:23
completed weeks
Serum Integrated
Without PlGF 11 81 2.5 1:11 85 3.6 1:15 87 4.6 1:19
12 80 2.7 1:12 83 3.9 1:16 86 5.0 1:20
13 79 2.9 1:13 83 4.2 1:18 85 5.4 1:22
With first 11 82 2.5 1:11 85 3.6 1:15 87 4.6 1:18
trimester PlGF 12 83 2.6 1:11 86 3.7 1:15 88 4.7 1:19
13 85 2.4 1:10 88 3.4 1:14 90 4.3 1:17
With second 11 82 2.3 1:10 85 3.3 1:14 87 4.3 1:17
trimester PlGF at 15 12 81 2.5 1:11 84 3.6 1:15 86 4.7 1:19
completed weeks 13 80 2.6 1:12 83 3.9 1:16 85 4.9 1:20
Integrated
Without PlGF 11 89 1.3 1:5 91 1.9 1:7 92 2.4 1:9
12 88 1.4 1:6 90 2.0 1:8 91 2.6 1:10
13 86 1.6 1:7 88 2.4 1:10 89 3.0 1:12
With first 11 90 1.3 1:5 91 1.8 1:7 92 2.3 1:9
trimester PlGF 12 89 1.3 1:5 91 1.9 1:7 92 2.4 1:9
13 90 1.4 1:5 91 1.9 1:7 93 2.4 1:9
With second 11 89 1.2 1:5 91 1.7 1:7 92 2.2 1:8
trimester PlGF at 15 12 88 1.3 1:5 90 1.9 1:7 91 2.4 1:9
completed weeks 13 86 1.5 1:6 88 2.2 1:9 90 2.8 1:11
doi:10.1371/journal.pone.0046955.t004
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PlGF to the Combined, serum Integrated and Integrated tests
increases over these weeks. For example, with the Combined test,
the addition of PlGF at 11 completed weeks’ of pregnancy
decreases the false-positive rate at a 90% detection rate by 0.6
percentage points (6.1% v 6.7%) but by 6 percentage points at 13
weeks (5.1% v 11.1%). Other first trimester studies on PlGF do not
report results by individual weeks. Their overall results are
consistent with ours in four studies[3–6], but not in one. [7].
The screening performance of the Combined (and also the
serum Integrated test) is best if the first trimester markers,
including PlGF, are measured at 13 completed weeks. However,
the performance of the Integrated test is similar when the first
trimester markers, including PlGF, are measured at 11, 12 or 13
completed weeks; the addition of PlGF thus removes the
advantage of performing the first stage of an Integrated test at
11 weeks compared with 12 or 13 weeks.
In the early second trimester of pregnancy PlGF values in Down
syndrome pregnancies tend to be reduced, but increase towards the
normal median with increasing gestation, possibly increasing above
the median and the standard deviation of second trimester values is
greater than that of first trimester values. Both of these effects mean
that the measurement of PlGF in the second trimester does not offer
a clinically significant improvement in screening performance.
We used a linear regression model in the first trimester and a
separate linear regression in the second trimester to quantify the
PlGF levels in affected pregnancies according to gestational age;
both regression models fitted the data reasonably well (see
Figure 2), and fitted better than a single quadratic regression
using all the data together. Separate linear regressions also have
the advantage of being more stable.
PlGF has been shown to be a useful marker in prenatal
screening for pre-eclampsia in both the first and second trimesters
of pregnancy. [1,2] A first trimester PlGF measurement could be
used as part of the Combined, serum Integrated or Integrated tests
for Down syndrome as well as in screening for pre-eclampsia.
There is some benefit for a second trimester measurement of PlGF
if women book too late for a Combined, serum Integrated or
Integrated test even though the improvement in the performance
of antenatal screening for Down syndrome is small.
In estimating screening performance using first trimester
markers alone compared with that using the Integrated test
markers, there can be bias if the first trimester markers are
associated with miscarriage at about 10–14 weeks. This, for
example, affects PAPP-A, in which low values are associated with
miscarriage as well as with Down syndrome. [12] Any effect of
PlGF being associated with miscarriage in this period is likely to be
small, if present at all, because in our data there wase no
significant difference in the median PlGF MoM in affected
pregnancies tested using the Combined test and those tested using
the Integrated test (0.70 and 0.66 respectively, p = 0.35).
The financial cost of including first trimester PlGF measurement
in the Combined, Serum Integrated and Integrated tests depends on
when the first trimester markers are measured. If measured at 11
weeks, the cost per Down syndrome pregnancy diagnosed is about
£300 more expensive with the Combined test and £600 more
expensive with the Integrated test. Measured at 12 weeks, costs are
£2,500 less for the Combined test and £100 less for the Integrated
test; if measured at 13 weeks, the amounts are £7,100 and £1,700
less respectively. These estimates are based on using the unit costs
given in SURUSS12 increased by 25% to allow for inflation. Overall,
therefore, the addition of PlGF at 11–13 weeks is probably
worthwhile, given the improvement in screening performance with
little or no increased cost per Down syndrome pregnancy diagnosed.
Conclusion
This study, based on 532 Down syndrome pregnancies, is the
largest to have investigated the value of PlGF in antenatal
screening for Down syndrome. It shows that PlGF is a useful
Down syndrome screening marker in the late first trimester of
pregnancy but of little value when measured in the early second
trimester. Women having a Combined, serum Integrated or
Integrated test should have PlGF measured in the first trimester
and women having the Quadruple test need only have PlGF
measured in the second trimester if the intention is to screen for
pre-eclampsia as well as for Down syndrome.
Supporting Information
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Table 5. Screening performance according to detection and
false-positive rates of the Combined, Quadruple and
Integrated tests with and without the addition of first
trimester (11–13 weeks1) or second trimester placental
growth factor (PlGF).
DR (%) for FPR of:- FPR (%) for DR of:-
Test 1% 3% 5% 85% 90% 95%
Combined
Without PlGF 73 82 86 4.4 8.8 19.8
With PlGF 77 85 89 2.7 5.8 14.2
Serum Integrated
Without PlGF 69 81 86 4.6 8.3 17.1
With first trimester
PlGF
74 85 89 3.1 5.7 12.2
With second trimester
PlGF
71 82 87 4.0 7.5 15.8
Integrated
Without PlGF 85 91 94 1.0 2.4 6.9
With first trimester
PlGF
88 93 95 0.6 1.5 4.4
With second trimester
PlGF
87 92 94 0.8 2.0 6.1
1Average of the individual estimates with first trimester markers measured at
11, 12 and 13 completed weeks of gestation (see Table 3), assuming equal
numbers of women screened at each week.
doi:10.1371/journal.pone.0046955.t005
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